3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
2
Thrombophilia
1
Rectal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
EGFR-Mutant Lung Cancer
1
Deglutition Disorders
1
Communication Disorders
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Brain Neoplasms
1
Blood Coagulation Disorders
1
Adenocarcinoma
1
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
Lead
×
Clear all
NCT00532155
2025-09-10
VITAL
Sanofi
Phase 3
Completed
913 enrolled
16 charts